Skip to main content

REPARACION DEL DNA Y ANEMIA DE FANCONI: INVESTIGACION GENETICA Y APLICACIONES TERAPEUTICAS

SAF2015-64152-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2015
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Dirección General de Investigación Científica y Técnica
Beneficiary centre UNIVERSIDAD AUTONOMA DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

NHEJ-Mediated Repair of CRISPR-Cas9-Induced DNA Breaks Efficiently Corrects Mutations in HSPCs from Patients with Fanconi Anemia.

  • Román-Rodríguez, Francisco José
  • Ugalde, Laura
  • Álvarez, Lara
  • Díez, Begoña
  • Ramírez, María José
  • Risueño, Cristina
  • Cortón, Marta
  • Bogliolo, Massimo
  • Bernal, Sara
  • March, Francesca
  • Ayuso, Carmen
  • Hanenberg, Helmut
  • Sevilla, Julián
  • Rodriguez Perales, Sandra
  • Torres-Ruiz, Raul
  • Surrallés, Jordi
  • Bueren, Juan Antonio
  • Río, Paula
Non-homologous end-joining (NHEJ) is the preferred mechanism used by hematopoietic stem cells (HSCs) to repair double-stranded DNA breaks and is particularly increased in cells deficient in the Fanconi anemia (FA) pathway. Here, we show feasible correction of compromised functional phenotypes in hematopoietic cells from multiple FA complementation groups, including FA-A, FA-C, FA-D1, and FA-D2. NHEJ-mediated repair of targeted CRISPR-Cas9-induced DNA breaks generated compensatory insertions and deletions that restore the coding frame of the mutated gene. NHEJ-mediated editing efficacy was initially verified in FA lymphoblastic cell lines and then in primary FA patient-derived CD34 cells, which showed marked proliferative advantage and phenotypic correction both in vitro and after transplantation. Importantly, and in contrast to homologous directed repair, NHEJ efficiently targeted primitive human HSCs, indicating that NHEJ editing approaches may constitute a sound alternative for editing self-renewing human HSCs and consequently for treatment of FA and other monogenic diseases affecting the hematopoietic system.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1

  • Hernández, Gonzalo
  • Ramírez, María José
  • Minguillón, Jordi
  • Quiles, Paco
  • Ruiz de Garibay, Gorka
  • Aza Carmona, Miriam
  • Bogliolo, Massimo
  • Pujol, Roser
  • Prados-Carvajal, Rosario
  • Fernández, Juana
  • García, Nadia
  • López, Adrià
  • Gutiérrez-Enríquez, Sara
  • Díez, Orland
  • Benitez, Javier
  • Salinas, Mónica
  • Teulé, Alex
  • Brunet, Joan
  • Radice, Paolo
  • Peterlongo, Paolo
  • Schindler, Detlev
  • Huertas Sánchez, Pablo
  • Puente, Xose S.
  • Lázaro, Conxi
  • Pujana, Miguel Ángel
  • Surrallés, Jordi
BRCA1 is a tumor suppressor that regulates DNA repair by homologous recombination. Germline mutations in BRCA1 are associated with increased risk of breast and ovarian cancer and BRCA1 deficient tumors are exquisitely sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. Therefore, uncovering additional components of this DNA repair pathway is of extreme importance for further understanding cancer development and therapeutic vulnerabilities. Here, we identify EDC4, a known component of processing-bodies and regulator of mRNA decapping, as a member of the BRCA1-BRIP1-TOPBP1 complex. EDC4 plays a key role in homologous recombination by stimulating end resection at double-strand breaks. EDC4 deficiency leads to genome instability and hypersensitivity to DNA interstrand crosslinking drugs and PARP inhibitors. Lack-of-function mutations in EDC4 were detected in BRCA1/2-mutation-negative breast cancer cases, suggesting a role in breast cancer susceptibility. Collectively, this study recognizes EDC4 with a dual role in decapping and DNA repair whose inactivation phenocopies BRCA1 deficiency, Surrallés laboratory is supported by the ICREA-Academia program, the Marató de TV3 (project 464/C/2012), the Spanish Ministry of Health (projects FANCOSTEM and FANCOLEN), the Spanish Ministry of Economy and Competiveness (projects CB06/07/0023, SAF2012-31881, SAF2013-45836-R and SAF2015-64152-R), the European Commission (EUROFANCOLEN project HEALTH-F5-2012-305421 and P-SPHERE COFUND project), the Fanconi Anemia Research Fund Inc., and the “Fondo Europeo de Desarrollo Regional, una manera de hacer Europa” (FEDER). CIBERER is an initiative of the Instituto de Salud Carlos III, Spain. This work was also supported by grants from the Asociación Española Contra el Cáncer (AECC, Hereditary Cancer group, 2010), the Generalitat de Catalunya (SGR 2014-364 and 2014-338), and the Instituto de Salud Carlos III (PIE13/00022-ONCOPROFILE, CP10/00617, PI10/01422, PI12/02585, PI13/00285, PI15/00854, PI16/00563, PI16/01218, and RTICC RD12/0036/0008). S.G.-E. is funded by a Miguel Servet contract from the Instituto de Salud Carlos III., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1

  • Hernández, Gonzalo
  • Ramírez, María José
  • Minguillón, Jordi
  • Quiles, Paco
  • Ruiz de Garibay, Gorka
  • Aza-Carmona, Miriam
  • Bogliolo, Massimo
  • Pujol, Roser
  • Prados-Carvajal, Rosario
  • Fernández, Juana
  • García, Nadia
  • López, Adrià
  • Gutiérrez-Enríquez, Sara
  • Diez, Orland
  • Benítez, Javier
  • Salinas, Mónica
  • Teulé, Alex
  • Brunet, Joan
  • Radice, Paolo
  • Peterlongo, Paolo
  • Schindler, Detlev
  • Huertas, Pablo
  • Puente, Xose S.
  • Lázaro, Conxi
  • Pujana, Miquel Àngel
  • Surrallés, Jordi
We thank Dr. Andre Nussenzweig and Dr. Elsa Callen for critical reading of the manuscript and helpful comments and Dr. Joaquin Dopazo for his help with the CIBERER Spanish Variant Server. Surrallés laboratory is supported by the ICREAAcademia program, the Marató de TV3 (project 464/C/2012), the Spanish Ministry of Health (projects FANCOSTEM and FANCOLEN), the Spanish Ministry of Economy and Competiveness (projects CB06/07/0023, SAF2012-31881, SAF2013-45836-R and SAF2015-64152-R), the European Commission (EUROFANCOLEN project HEALTHF5-2012-305421 and P-SPHERE COFUND project), the Fanconi Anemia Research Fund Inc., and the “Fondo Europeo de Desarrollo Regional, una manera de hacer Europa” (FEDER). CIBERER is an initiative of the Instituto de Salud Carlos III, Spain. This work was also supported by grants from the Asociación Española Contra el Cáncer (AECC, Hereditary Cancer group, 2010), the Generalitat de Catalunya (SGR 2014-364 and 2014-338), and the Instituto de Salud Carlos III (PIE13/00022-ONCOPROFILE, CP10/00617, PI10/01422, PI12/02585, PI13/00285, PI15/00854, PI16/00563, PI16/01218, and RTICC RD12/0036/0008). S.G.-E. is funded by a Miguel Servet contract from the Instituto de Salud Carlos III., BRCA1 is a tumor suppressor that regulates DNA repair by homologous recombination. Germline mutations in BRCA1 are associated with increased risk of breast and ovarian cancer and BRCA1 deficient tumors are exquisitely sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. Therefore, uncovering additional components of this DNA repair pathway is of extreme importance for further understanding cancer development and therapeutic vulnerabilities. Here, we identify EDC4, a known component of processing-bodies and regulator of mRNA decapping, as a member of the BRCA1-BRIP1-TOPBP1 complex. EDC4 plays a key role in homologous recombination by stimulating end resection at double-strand breaks. EDC4 deficiency leads to genome instability and hypersensitivity to DNA interstrand cross-linking drugs and PARP inhibitors. Lack-of-function mutations in EDC4 were detected in BRCA1/2-mutation-negative breast cancer cases, suggesting a role in breast cancer susceptibility. Collectively, this study recognizes EDC4 with a dual role in decapping and DNA repair whose inactivation phenocopies BRCA1 deficiency., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Detectable clonal mosaicism in blood as biomarker of cancer risk in Fanconi anemia

  • Reina-Castillón, Judith
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • López Sánchez, Marcos|||0000-0002-1517-5968
  • Surralles, Jordi|||0000-0002-4041-7519
Detectable clonal mosaicism for large chromosomal events has been associated with aging and an increased risk of hematological and some solid cancers. We hypothesized that genetic cancer predisposition disorders, such as Fanconi anemia (FA), could manifest a high rate of chromosomal mosaic events (CMEs) in peripheral blood, which could be used as early biomarkers of cancer risk. We studied the prevalence of CMEs by single-nucleotide polymorphism (SNP) array in 130 FA patients' blood DNA and their impact on cancer risk. We detected 51 CMEs (4.4-159 Mb in size) in 16 out of 130 patients (12.3%), of which 9 had multiple CMEs. The most frequent events were gains at 3q (n = 6) and 1q (n = 5), both previously associated with leukemia, as well as rearrangements with breakpoint clustering within the major histocompatibility complex locus (P = 7.3 × 10-9). Compared with 15?743 age-matched population controls, FA patients had a 126 to 140 times higher risk of detectable CMEs in blood (P < 2.2 × 10-16). Prevalent and incident hematologic and solid cancers were more common in CME carriers (odds ratio [OR] = 11.6, 95% confidence interval [CI] = 3.4-39.3, P = 2.8 × 10-5), leading to poorer prognosis. The age-adjusted hazard risk (HR) of having cancer was almost 5 times higher in FA individuals with CMEs than in those without CMEs. Regarding survival, the HR of dying was 4 times higher in FA individuals having CMEs (HR = 4.0, 95% CI = 2.0-7.9, P = 5.7 × 10-5). Therefore, our data suggest that molecular karyotyping with SNP arrays in easy-to-obtain blood samples could be used for better monitoring of bone marrow clonal events, cancer risk, and overall survival of FA patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Individuals with FANCM biallelic mutations do no develop Fanconi anemia, but show risk for breast cancer, chemotherapy sensitivity toxicity and may display chromosome fragility

  • Catucci, Irene
  • Osorio, Ana|||0000-0001-8124-3984
  • Arver, Brita
  • Neidhardt, Guido
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Zanardi, Federica
  • Riboni, Mirko
  • Minardi, Simone
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Azzollini, Jacopo
  • Peissel, Bernard|||0000-0001-9233-3571
  • Manoukian, Siranoush
  • Vecchi, De, Giovanna
  • Casola, Stefano
  • Hauke, Jan|||0000-0001-8236-4075
  • Richters, Lisa
  • Rhiem, Kerstin
  • Schmutzler, Rita K.
  • Wallander, Karin
  • Törngren, Therese
  • Borg, Åke
  • Radice, Paolo|||0000-0001-6298-4111
  • Surralles, Jordi|||0000-0002-4041-7519
  • Hahnen, Eric|||0000-0002-1152-8367
  • Ehrencrona, Hans|||0000-0002-5589-3622
  • Kvist, Anders
  • Benitez, Javier|||0000-0002-0923-7202
  • Peterlongo, Paolo|||0000-0001-6951-6855
PurposeMonoallelic germ-line mutations in the BRCA1/FANCS, BRCA2/FANCD1 and PALB2/FANCN genes confer high risk of breast cancer. Biallelic mutations in these genes cause Fanconi anemia (FA), characterized by malformations, bone marrow failure, chromosome fragility, and cancer predisposition (BRCA2/FANCD1 and PALB2/FANCN), or an FA-like disease presenting a phenotype similar to FA but without bone marrow failure (BRCA1/FANCS). FANCM monoallelic mutations have been reported as moderate risk factors for breast cancer, but there are no reports of any clinical phenotype observed in carriers of biallelic mutations.MethodsBreast cancer probands were subjected to mutation analysis by sequencing gene panels or testing DNA damage response genes.ResultsFive cases homozygous for FANCM loss-of-function mutations were identified. They show a heterogeneous phenotype including cancer predisposition, toxicity to chemotherapy, early menopause, and possibly chromosome fragility. Phenotype severity might correlate with mutation position in the gene.ConclusionOur data indicate that biallelic FANCM mutations do not cause classical FA, providing proof that FANCM is not a canonical FA gene. Moreover, our observations support previous findings suggesting that FANCM is a breast cancer-predisposing gene. Mutation testing of FANCM might be considered for individuals with the above-described clinical features.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1

  • Hernández Viedma, Gonzalo|||0000-0002-3048-9607
  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Minguillón Pedreño, Jordi|||0000-0003-2124-8294
  • Quiles, Francisco
  • Ruiz de Garibay, G.
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Prados-Carvajal, Rosario
  • Fernández-Rodríguez, Juana
  • García, Nadia
  • López, Adrià
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Diez, Orland|||0000-0001-7339-0570
  • Benitez, Javier|||0000-0002-0923-7202
  • Salinas, Monica
  • Teule, Alex|||0000-0003-0028-7200
  • Brunet, Joan|||0000-0003-1945-3512
  • Radice, Paolo|||0000-0001-6298-4111
  • Peterlongo, Paolo|||0000-0001-6951-6855
  • Schindler, Detlev
  • Huertas, Pablo
  • Puente, Xose P.
  • Lázaro, Coxi
  • Pujana, Miguel Angel|||0000-0003-3222-4044
  • Surralles, Jordi|||0000-0002-4041-7519
BRCA1 is a tumor suppressor that regulates DNA repair by homologous recombination. Germline mutations in BRCA1 are associated with increased risk of breast and ovarian cancer and BRCA1 deficient tumors are exquisitely sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. Therefore, uncovering additional components of this DNA repair pathway is of extreme importance for further understanding cancer development and therapeutic vulnerabilities. Here, we identify EDC4, a known component of processing-bodies and regulator of mRNA decapping, as a member of the BRCA1-BRIP1-TOPBP1 complex. EDC4 plays a key role in homologous recombination by stimulating end resection at double-strand breaks. EDC4 deficiency leads to genome instability and hypersensitivity to DNA interstrand cross-linking drugs and PARP inhibitors. Lack-of-function mutations in EDC4 were detected in BRCA1/2-mutation-negative breast cancer cases, suggesting a role in breast cancer susceptibility. Collectively, this study recognizes EDC4 with a dual role in decapping and DNA repair whose inactivation phenocopies BRCA1 deficiency.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

From exome analysis in idiopathic azoospermia to the identification of a high-risk subgroup for occult Fanconi anemia

  • Krausz, Csilla|||0000-0001-6748-8918
  • Riera-Escamilla, Antoni|||0000-0002-4485-3094
  • Chianese, Chiara|||0000-0002-8952-0584
  • Moreno-Mendoza, Daniel
  • Ars, Elisabet|||0000-0002-4118-4358
  • Rajmil Marquenson, Osvlado|||0000-0003-1987-9206
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Rodríguez, Inés
  • Badell Serra, Isabel|||0000-0001-6546-2175
  • Ruiz-Castañé, Eduardo|||0000-0002-7469-4610
  • Surralles, Jordi|||0000-0002-4041-7519
Purpose: in about 10% of patients affected by Fanconi anemia (FA) the diagnosis is delayed until adulthood, and the presenting symptom in these "occult" FA cases is often a solid cancer and cancer treatment-related toxicity. Highly predictive clinical parameter(s) for diagnosing such an adult-onset cases are missing. - Methods: (1) Exome sequencing (ES), (2) Sanger sequencing of FANCA, (3) diepoxybutane (DEB)-induced chromosome breakage test. - Results: ES identified a pathogenic homozygous FANCA variant in a patient affected by Sertoli cell-only syndrome (SCOS) and in his azoospermic brother. Although they had no overt anemia, chromosomal breakage test revealed a reverse somatic mosaicism in the former and a typical FA picture in the latter. In 27 selected SCOS cases, 1 additional patient showing compound heterozygous pathogenic FANCA variants was identified with positive chromosomal breakage test. - Conclusion: we report an extraordinarily high frequency of FA in a specific subgroup of azoospermic patients (7.1%). The screening for FANCA pathogenic variants in such patients has the potential to identify undiagnosed FA before the appearance of other severe clinical manifestations of the disease. The definition of this high-risk group for "occult" FA, based on specific testis phenotype with mild/borderline hematological alterations, is of unforeseen clinical relevance.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Mutations in TOP3A Cause a Bloom Syndrome-like Disorder

  • Martin, Carol-Anne
  • Sarlós, Kata
  • Logan, Clare V.
  • Singh Thakur, Roshan
  • Parry, David A.
  • Bizard, Anna H.
  • Leitch, Andrea
  • Cleal, Louise
  • Shaukat Ali, Nadia
  • Al-Owain, Mohammed A.
  • Allen, William
  • Altmüller, Janine|||0000-0003-4372-1521
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Barakat, Bushra A. Y.
  • Barraza-García, Jimena
  • Begtrup, Amber
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Cho, Megan T.
  • Cruz-Rojo, Jaime
  • Mundi Dhahrabi, Hassan Ali
  • Elcioglu, Nursel H.
  • Gorman, Gráinne S.|||0000-0002-7585-3409
  • Jobling, Rebekah
  • Kesterton, Ian
  • Kishita, Yoshihito
  • Kohda, Masakazu
  • Quesne Stabej, Polona Le
  • Jassim Malallah, Asam
  • Nürnberg, Peter
  • Ohtake, Akira
  • Okazaki, Yasushi
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Revah-Politi, Anya
  • Shimura, Masaru
  • Stevens, Paul
  • Taylor, Robert W.|||0000-0002-7768-8873
  • Turner, Lesley
  • Williams, Hywel
  • Wilson, Carolyn
  • Yigit, Gökhan
  • Zahavich, Laura
  • Alkuraya, Fowzan S.|||0000-0003-4158-341X
  • Surralles, Jordi|||0000-0002-4041-7519
  • Iglesias, Alejandro
  • Murayama, Kei
  • Wollnik, Bernd|||0000-0003-2589-0364
  • Dattani, Mehul
  • Heath, Karen E.
  • Hickson, Ian D.
  • Jackson, Andrew P.
Bloom syndrome, caused by biallelic mutations in BLM, is characterized by prenatal-onset growth deficiency, short stature, an erythematous photosensitive malar rash, and increased cancer predisposition. Diagnostically, a hallmark feature is the presence of increased sister chromatid exchanges (SCEs) on cytogenetic testing. Here, we describe biallelic mutations in TOP3A in ten individuals with prenatalonset growth restriction and microcephaly. TOP3A encodes topoisomerase III alpha (TopIIIa), which binds to BLM as part of the BTRR complex, and promotes dissolution of double Holliday junctions arising during homologous recombination. We also identify a homozygous truncating variant in RMI1, which encodes another component of the BTRR complex, in two individuals with microcephalic dwarfism. The TOP3A mutations substantially reduce cellular levels of TopIIIa, and consequently subjects' cells demonstrate elevated rates of SCE. Unresolved DNA recombination and/or replication intermediates persist into mitosis, leading to chromosome segregation defects and genome instability that most likely explain the growth restriction seen in these subjects and in Bloom syndrome. Clinical features of mitochondrial dysfunction are evident in several individuals with biallelic TOP3A mutations, consistent with the recently reported additional function of TopIIIa in mitochondrial DNA decatenation. In summary, our findings establish TOP3A mutations as an additional cause of prenatal-onset short stature with increased cytogenetic SCEs and implicate the decatenation activity of the BTRR complex in their pathogenesis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Functional comparison of XPF missense mutations associated to multiple DNA repair disorders

  • Marín, Maria
  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Jia, Nan
  • Ogi, Tomoo
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Surralles, Jordi|||0000-0002-4041-7519
XPF endonuclease is one of the most important DNA repair proteins. Encoded by XPF/ERCC4, XPF provides the enzymatic activity of XPF-ERCC1 heterodimer, an endonuclease that incises at the 5' side of various DNA lesions. XPF is essential for nucleotide excision repair (NER) and interstrand crosslink repair (ICLR). XPF/ERCC4 mutations are associated with several human diseases: Xeroderma Pigmentosum (XP), Segmental Progeria (XFE), Fanconi Anemia (FA), Cockayne Syndrome (CS), and XP/CS combined disease (XPCSCD). Most affected individuals are compound heterozygotes for XPF/ERCC4 mutations complicating the identification of genotype/phenotype correlations. We report a detailed overview of NER and ICLR functional studies in human XPF-KO (knock-out) isogenic cells expressing six disease-specific pathogenic XPF amino acid substitution mutations. Ultraviolet (UV) sensitivity and unscheduled DNA synthesis (UDS) assays provide the most reliable information to discern mutations associated with ICLR impairment from mutations related to NER deficiency, whereas recovery of RNA synthesis (RRS) assays results hint to a possible role of XPF in resolving R-loops. Our functional studies demonstrate that a defined cellular phenotype cannot be easily correlated to each XPF mutation. Substituted positions along XPF sequences are not predictive of cellular phenotype nor reflect a particular disease. Therefore, in addition to mutation type, allelic interactions, protein stability and intracellular distribution of mutant proteins may also contribute to alter DNA repair pathways balance leading to clinically distinct disorders.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Biallelic germline BRCA1 mutations in a patient with early onset breast cancer, mild Fanconi anemia-like phenotype, and no chromosome fragility

  • Keupp, Katharina
  • Hampp, Stephanie
  • Hübbel, Annette
  • Maringa, Monika
  • Kostezka, Sarah
  • Rhiem, Kerstin
  • Waha, Anke
  • Wappenschmidt, Barbara
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Surralles, Jordi|||0000-0002-4041-7519
  • Schmutzler, Rita K.
  • Wiesmüller, Lisa
  • Hahnen, Eric|||0000-0002-1152-8367
Background: Biallelic BRCA1 mutations are regarded either embryonically lethal or to cause Fanconi anemia (FA), a genomic instability syndrome characterized by bone marrow failure, developmental abnormalities, and cancer predisposition. We report biallelic BRCA1 mutations c.181T.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

High content drug screening for Fanconi anemia therapeutics

  • Montanuy, Helena
  • Camps-Fajol, Cristina
  • Carreras-Puigvert, Jordi
  • Häggblad, Maria
  • Lundgren, Bo
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Helleday, Thomas|||0000-0002-7384-092X
  • Minguillón Pedreño, Jordi|||0000-0003-2124-8294
  • Surralles, Jordi|||0000-0002-4041-7519
Fanconi anemia is a rare disease clinically characterized by malformations, bone marrow failure and an increased risk of solid tumors and hematologic malignancies. The only therapies available are hematopoietic stem cell transplantation for bone marrow failure or leukemia, and surgical resection for solid tumors. Therefore, there is still an urgent need for new therapeutic options. With this aim, we developed a novel high-content cell-based screening assay to identify drugs with therapeutic potential in FA. A TALEN-mediated FANCA-deficient U2OS cell line was stably transfected with YFP-FANCD2 fusion protein. These cells were unable to form fluorescent foci or to monoubiquitinate endogenous or exogenous FANCD2 upon DNA damage and were more sensitive to mitomycin C when compared to the parental wild type counterpart. FANCA correction by retroviral infection restored the cell line's ability to form FANCD2 foci and ubiquitinate FANCD2. The feasibility of this cell-based system was interrogated in a high content screening of 3802 compounds, including a Prestwick library of 1200 FDA-approved drugs. The potential hits identified were then individually tested for their ability to rescue FANCD2 foci and monoubiquitination, and chromosomal stability in the absence of FANCA. While, unfortunately, none of the compounds tested were able to restore cellular FANCA-deficiency, our study shows the potential capacity to screen large compound libraries in the context of Fanconi anemia therapeutics in an optimized and cost-effective platform.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Upregulation of NKG2D ligands impairs hematopoietic stem cell function in Fanconi anemia

  • Casado, José A.|||0000-0003-2479-1508
  • Valeri, A.
  • Sánchez Domínguez, Rebeca
  • Vela, Paula
  • Lopez, A.
  • Navarro Ordóñez, Susana|||0000-0002-0764-5384
  • Alberquilla, Omaira|||0000-0002-0301-8340
  • Hanenberg, H.
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Segovia, J. C.
  • Minguillon, J.
  • Surralles, Jordi|||0000-0002-4041-7519
  • De Heredia, C.D.
  • Sevilla, J.
  • Rio, P.
  • Bueren, Juan|||0000-0002-3228-7013
Fanconi anemia (FA) is the most prevalent inherited bone marrow failure (BMF) syndrome. Nevertheless, the pathophysiological mechanisms of BMF in FA have not been fully elucidated. Since FA cells are defective in DNA repair, we hypothesized that FA hematopoietic stem and progenitor cells (HSPCs) might express DNA damage-associated stress molecules such as natural killer group 2 member D ligands (NKG2D-Ls). These ligands could then interact with the activating NKG2D receptor expressed in cytotoxic NK or CD8+ T cells, which may result in progressive HSPC depletion. Our results indeed demonstrated upregulated levels of NKG2D-Ls in cultured FA fibroblasts and T cells, and these levels were further exacerbated by mitomycin C or formaldehyde. Notably, a high proportion of BM CD34+ HSPCs from patients with FA also expressed increased levels of NKG2D-Ls, which correlated inversely with the percentage of CD34+ cells in BM. Remarkably, the reduced clonogenic potential characteristic of FA HSPCs was improved by blocking NKG2D-NKG2D-L interactions. Moreover, the in vivo blockage of these interactions in a BMF FA mouse model ameliorated the anemia in these animals. Our study demonstrates the involvement of NKG2D-NKG2D-L interactions in FA HSPC functionality, suggesting an unexpected role of the immune system in the progressive BMF that is characteristic of FA.